What is Mounjaro?
Mounjaro is a diabetes and weight-loss drug developed by Eli Lilly.
Yanuki
ARTICLE DETAIL
Eli Lilly's Mounjaro Sees Strong Demand in India Amid Rising Obesity | Live Nation and Justice Department Reach Settlement in Antitrust Case | Walmart vs BJ’s Wholesale: Which Retailer Is the Better Buy? | Byron Allen Acquires Stake in Starz: What It Means for the Media Landscape | Exxon Mobil Stock Soars on Swiss Exchange Amid Record Volume | Stock Market Plunge: Sensex Tumbles as Oil Surges Amid Iran War Fears | Oil Prices Surge, Stocks Drop After Weak U.S. Job Market Update | Oil Prices Surge Amid Iran Conflict: Will Strategic Petroleum Reserve Be Tapped? | Lloyd Blankfein on Wall Street Crises: Past and Future | Eli Lilly's Mounjaro Sees Strong Demand in India Amid Rising Obesity | Live Nation and Justice Department Reach Settlement in Antitrust Case | Walmart vs BJ’s Wholesale: Which Retailer Is the Better Buy? | Byron Allen Acquires Stake in Starz: What It Means for the Media Landscape | Exxon Mobil Stock Soars on Swiss Exchange Amid Record Volume | Stock Market Plunge: Sensex Tumbles as Oil Surges Amid Iran War Fears | Oil Prices Surge, Stocks Drop After Weak U.S. Job Market Update | Oil Prices Surge Amid Iran Conflict: Will Strategic Petroleum Reserve Be Tapped? | Lloyd Blankfein on Wall Street Crises: Past and Future
Business / Pharmaceuticals
Eli Lilly's Mounjaro Sees Strong Demand in India Amid Rising Obesity
Eli Lilly (LLY) is witnessing robust demand for its diabetes and weight-loss drug, Mounjaro, in India, driven by increasing rates of obesity and diabetes. The company is focused on meeting this rising demand, positioning Mounjaro as a key p...
Key Insights
- Mounjaro sales in India have seen a 60% increase between April and May, with over 81,570 units sold, totaling approximately 239.4 million rupees ($2.76 million).
- India faces a growing obesity crisis, with a quarter of people aged 15-49 being overweight or obese between 2019 and 2021, up from previous years.
- The number of adults with diabetes in India is projected to increase to over 124 million by 2045, from 74.2 million in 2021.
- Eli Lilly beat rival Novo Nordisk to introduce its drug in India, pricing it for the mass market.
- The Indian market for obesity and diabetes management is estimated to be worth around $150 billion by the early 2030s.
In-Depth Analysis
**Market Dynamics:** India's growing affluence has contributed to increased obesity and diabetes rates. Government surveys indicate a rise in overweight and obese individuals, creating a substantial market for weight-loss and diabetes management drugs. Eli Lilly's Mounjaro has gained traction, selling over 81,570 units, reflecting a 60% sales increase between April and May.
**Competitive Landscape:** Eli Lilly was the first to introduce its weight-loss drug in India, beating Novo Nordisk. However, Indian drugmakers are racing to produce cheaper versions, intensifying competition. Novo Nordisk is also expected to launch its weight-loss drug, Wegovy, in India next year, further shaping the market dynamics.
**Financial Performance:** In Q1 2025, Eli Lilly reported a 45% increase in revenue compared to Q1 2024. Mounjaro sales reached $3.8 billion, more than double the previous year. While marketing and R&D expenses increased, the company saw significant revenue growth in the US, Europe, Japan, and China.
**Actionable Takeaways:** - Monitor Eli Lilly's market share and sales growth in India. - Keep an eye on the competitive landscape, including the entry of Novo Nordisk's Wegovy and the development of cheaper alternatives by Indian drugmakers. - Understand the evolving regulatory environment and pricing strategies in the Indian pharmaceutical market.
FAQ
Why is Mounjaro gaining popularity in India?
Due to the increasing rates of obesity and diabetes in the country.
What is the estimated market size for obesity and diabetes management in India?
Approximately $150 billion by the early 2030s.
Takeaways
- Eli Lilly's Mounjaro is experiencing strong demand in India due to rising obesity and diabetes rates.
- The Indian market presents a significant opportunity for pharmaceutical companies.
- Competition is expected to intensify with the entry of new players and the development of cheaper alternatives.
Discussion
Do you think Eli Lilly will maintain its lead in the Indian market despite increasing competition? Share your thoughts in the comments!
Share this article with others who need to stay ahead of this trend!
Sources
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.